Zenoxa OD 150 Tablet SR contains Oxcarbazepine 150 mg, an antiepileptic agent primarily indicated for the treatment of partial seizures with or without secondary generalization in adults and children aged 4 years and above. Oxcarbazepine acts by stabilizing hyperexcited neural membranes, inhibiting repetitive neuronal firing, and reducing the propagation of seizure activity through modulation of voltage-sensitive sodium channels. The sustained-release (SR) formulation ensures a controlled and prolonged release of the active ingredient, promoting consistent plasma levels and improving patient compliance by allowing once-daily dosing. Zenoxa OD 150 Tablet SR is generally well-tolerated; however, clinicians should monitor for potential adverse effects including dizziness, somnolence, headache, nausea, and hyponatremia. Caution is advised in patients with a history of hypersensitivity to carbamazepine or oxcarbazepine, as cross-reactivity may occur. Regular monitoring of serum sodium levels is recommended, especially during the initial months of therapy or in patients at risk of electrolyte imbalance. Dose adjustments may be necessary in hepatic or renal impairment. Zenoxa OD 150 Tablet SR should be prescribed and administered under medical supervision, with careful consideration of drug interactions, particularly with other antiepileptic drugs, to optimize therapeutic outcomes and minimize adverse effects.